There is a need to improve personalized immunosuppression in organ transplantation to
reduce premature graft loss. Biomarkers are needed to better detect rejection, asymptomatic …

Noninvasive heart transplant rejection surveillance using gene expression profiling (GEP) to
monitor immune activation is widely used among heart transplant programs. With the new …

The number of heart transplants performed annually in the United States and worldwide
continues to increase, but there has been little change in graft longevity and patient survival …

While allograft rejection (AR) continues to threaten the success of cardiothoracic
transplantation, lack of accurate and repeatable surveillance tools to diagnose AR is a major …

Aims Current non-invasive screening methods for cardiac allograft rejection have shown
limited discrimination and are yet to be broadly integrated into heart transplant care. Given …

BACKGROUND: Heart transplant recipients with donor-specific antibodies (DSAs) have an
increased risk for antibody-mediated rejection. However, many patients with graft …

Background. The reference standard of detecting acute rejection (AR) in adult heart
transplant (HTx) patients is an endomyocardial biopsy (EMB). The majority of EMBs are …

Background. Standard-of-care biomarkers for renal allograft rejection are lagging indicators,
signaling existing organ injury. This precludes early intervention, when immunological …

The use of noninvasive biomarkers may reduce the need for biopsy and guide
immunosuppression adjustments during transplantation. The scientific community in solid …

Rejection surveillance after heart transplantation depends on endomyocardial biopsies.
Donor-derived cell-free DNA (dd-cfDNA) may offer a less invasive marker. In this prospective …